Profile data is unavailable for this security.
About the company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
- Revenue in USD (TTM)27.71m
- Net income in USD-284.69m
- Incorporated2012
- Employees480.00
- LocationUniqure NVPaasheuvelweg 25aAMSTERDAM 1105 BPNetherlandsNLD
- Phone+31 202406000
- Fax+31 202406020
- Websitehttp://www.uniqure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abeona Therapeutics Inc | 0.00 | -52.60m | 288.91m | 84.00 | -- | 3.79 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| PepGen Inc | 0.00 | -89.14m | 291.35m | 64.00 | -- | 1.87 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 293.51m | 17.00 | 4.58 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 295.57m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Lyell Immunopharma Inc | 54.00k | -210.26m | 299.52m | 224.00 | -- | 0.5286 | -- | 5,546.73 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Nkarta Inc | 0.00 | -107.91m | 300.58m | 150.00 | -- | 0.6633 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| ADC Therapeutics SA | 66.75m | -214.86m | 301.67m | 273.00 | -- | -- | -- | 4.52 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Jasper Therapeutics Inc | 0.00 | -62.44m | 302.71m | 45.00 | -- | 3.02 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 305.72m | 304.00 | -- | 2.01 | -- | 1.81 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| AC Immune SA | 17.91m | -69.98m | 309.68m | 133.00 | -- | 2.18 | -- | 17.29 | -0.7422 | -0.7422 | 0.1934 | 1.44 | 0.0787 | -- | 28.76 | 134,672.30 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Uniqure NV | 27.71m | -284.69m | 312.64m | 480.00 | -- | 3.22 | -- | 11.28 | -5.92 | -5.92 | 0.5754 | 1.99 | 0.0331 | 5.20 | 0.5019 | 57,722.92 | -34.02 | -12.43 | -37.34 | -13.46 | 4.26 | -- | -1,027.52 | -51.35 | 7.36 | -6.32 | 0.8422 | -- | -85.12 | 7.02 | -143.30 | -- | 11.00 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 313.77m | 14.00 | -- | 2.00 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 316.79m | 57.00 | -- | 1.21 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 322.49m | 75.00 | -- | 0.6768 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -64.20m | 336.64m | 9.00 | -- | 1.51 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Data as of Oct 18 2024. Currency figures normalised to Uniqure NV's reporting currency: US Dollar USD
36.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Vestal Point Capital LPas of 30 Jun 2024 | 4.75m | 9.75% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 2.65m | 5.44% |
| 683 Capital Management LLCas of 30 Jun 2024 | 1.90m | 3.90% |
| Schroder Investment Management Ltd.as of 30 Jun 2024 | 1.74m | 3.57% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.51m | 3.11% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 1.22m | 2.51% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.15m | 2.35% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.00m | 2.06% |
| Columbia Management Investment Advisers LLCas of 30 Jun 2024 | 851.07k | 1.75% |
| Hudson Bay Capital Management LPas of 30 Jun 2024 | 809.12k | 1.66% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
